Your browser doesn't support javascript.
loading
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Ott, Patrick A; Hu-Lieskovan, Siwen; Chmielowski, Bartosz; Govindan, Ramaswamy; Naing, Aung; Bhardwaj, Nina; Margolin, Kim; Awad, Mark M; Hellmann, Matthew D; Lin, Jessica J; Friedlander, Terence; Bushway, Meghan E; Balogh, Kristen N; Sciuto, Tracey E; Kohler, Victoria; Turnbull, Samantha J; Besada, Rana; Curran, Riley R; Trapp, Benjamin; Scherer, Julian; Poran, Asaf; Harjanto, Dewi; Barthelme, Dominik; Ting, Ying Sonia; Dong, Jesse Z; Ware, Yvonne; Huang, Yuting; Huang, Zhengping; Wanamaker, Amy; Cleary, Lisa D; Moles, Melissa A; Manson, Kelledy; Greshock, Joel; Khondker, Zakaria S; Fritsch, Ed; Rooney, Michael S; DeMario, Mark; Gaynor, Richard B; Srinivasan, Lakshmi.
Afiliación
  • Ott PA; Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. Electronic address: patrick_ott@dfci.harvard.edu.
  • Hu-Lieskovan S; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Chmielowski B; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Govindan R; Washington University School of Medicine, St. Louis, MO, USA.
  • Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bhardwaj N; Tisch Cancer Institute, Icahn School of Medicine, New York, NY, USA.
  • Margolin K; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
  • Awad MM; Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Hellmann MD; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lin JJ; Cancer Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.
  • Friedlander T; Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.
  • Bushway ME; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Balogh KN; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Sciuto TE; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Kohler V; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Turnbull SJ; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Besada R; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Curran RR; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Trapp B; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Scherer J; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Poran A; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Harjanto D; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Barthelme D; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Ting YS; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Dong JZ; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Ware Y; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Huang Y; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Huang Z; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Wanamaker A; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Cleary LD; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Moles MA; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Manson K; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Greshock J; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Khondker ZS; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Fritsch E; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Rooney MS; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • DeMario M; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Gaynor RB; Neon Therapeutics/BioNTech US, Cambridge, MA, USA.
  • Srinivasan L; Neon Therapeutics/BioNTech US, Cambridge, MA, USA. Electronic address: lakshmi.srinivasan@biontech.us.
Cell ; 183(2): 347-362.e24, 2020 10 15.
Article en En | MEDLINE | ID: mdl-33064988
ABSTRACT
Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. This analysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adverse events observed. De novo neoantigen-specific CD4+ and CD8+ T cell responses were observed post-vaccination in all of the patients. The vaccine-induced T cells had a cytotoxic phenotype and were capable of trafficking to the tumor and mediating cell killing. In addition, epitope spread to neoantigens not included in the vaccine was detected post-vaccination. These data support the safety and immunogenicity of this regimen in patients with advanced solid tumors (Clinicaltrials.gov NCT02897765).
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Medicina de Precisión / Inmunoterapia Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Medicina de Precisión / Inmunoterapia Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Año: 2020 Tipo del documento: Article